New aminocoumarin antibiotics from genetically engineered Streptomyces strains
- PMID:15720250
- DOI: 10.2174/0929867053363063
New aminocoumarin antibiotics from genetically engineered Streptomyces strains
Abstract
The aminocoumarin antibiotics novobiocin, clorobiocin and coumermycin A(1) are produced by different Streptomyces strains and are potent inhibitors of DNA gyrase. The biosynthetic gene clusters of all three antibiotics have been cloned and sequenced, and the function of most genes contained therein has been elucidated. In the last years, a number of "unnatural" aminocoumarins could be generated using the genetic information for the biosynthesis of these antibiotics. The investigated enzymes of aminocoumarin biosynthesis have less-than-perfect substrate specificity, facilitating the production of new antibiotics by various methods. Several new aminocoumarins could be produced by targeted genetic manipulation in the natural producers, but also in heterologous host Streptomyces coelicolor after expression of the respective gene cluster. Mutasynthesis experiments, i. e. generation of a cloQ-defective mutant of the clorobiocin producer and feeding of 13 different structural analogs of 3-dimethylallyl-4-hydroxybenzoic acid to this mutant, allowed the isolation of 32 new aminocoumarins. These compounds contained, instead of the genuine 3-dimethylallyl-4-hydroxybenzoyl moiety, the externally added analogs as the acyl components in their structures. Production of new aminocoumarins was also achieved by chemoenzymatic synthesis in vitro. Several biosynthetic enzymes have been heterologously expressed, purified und used for chemoenzymatic synthesis. The structures of the new aminocoumarins were elucidated by NMR and mass spectroscopy. Their inhibitory activity on gyrase in vitro as well as their antibacterial activity was determined. These results give further insight into the structure-activity relationships of aminocoumarins.
Similar articles
- Genetic engineering of antibiotic biosynthesis for the generation of new aminocoumarins.Heide L.Heide L.Biotechnol Adv. 2009 Nov-Dec;27(6):1006-1014. doi: 10.1016/j.biotechadv.2009.05.017. Epub 2009 May 20.Biotechnol Adv. 2009.PMID:19463934Review.
- Combinatorial biosynthesis, metabolic engineering and mutasynthesis for the generation of new aminocoumarin antibiotics.Heide L, Gust B, Anderle C, Li SM.Heide L, et al.Curr Top Med Chem. 2008;8(8):667-79. doi: 10.2174/156802608784221505.Curr Top Med Chem. 2008.PMID:18473891
- In vitro and in vivo production of new aminocoumarins by a combined biochemical, genetic, and synthetic approach.Galm U, Dessoy MA, Schmidt J, Wessjohann LA, Heide L.Galm U, et al.Chem Biol. 2004 Feb;11(2):173-83. doi: 10.1016/j.chembiol.2004.01.012.Chem Biol. 2004.PMID:15123279
- Aminocoumarins mutasynthesis, chemoenzymatic synthesis, and metabolic engineering.Heide L.Heide L.Methods Enzymol. 2009;459:437-55. doi: 10.1016/S0076-6879(09)04618-7.Methods Enzymol. 2009.PMID:19362650
- New aminocoumarin antibiotics as gyrase inhibitors.Heide L.Heide L.Int J Med Microbiol. 2014 Jan;304(1):31-6. doi: 10.1016/j.ijmm.2013.08.013. Epub 2013 Sep 4.Int J Med Microbiol. 2014.PMID:24079980Review.
Cited by
- The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace.Roca I, Espinal P, Vila-Farrés X, Vila J.Roca I, et al.Front Microbiol. 2012 Apr 23;3:148. doi: 10.3389/fmicb.2012.00148. eCollection 2012.Front Microbiol. 2012.PMID:22536199Free PMC article.
- Comparative analysis and insights into the evolution of gene clusters for glycopeptide antibiotic biosynthesis.Donadio S, Sosio M, Stegmann E, Weber T, Wohlleben W.Donadio S, et al.Mol Genet Genomics. 2005 Aug;274(1):40-50. doi: 10.1007/s00438-005-1156-3. Epub 2005 Jul 9.Mol Genet Genomics. 2005.PMID:16007453
- Metabolic engineering for the production of natural products.Pickens LB, Tang Y, Chooi YH.Pickens LB, et al.Annu Rev Chem Biomol Eng. 2011;2:211-36. doi: 10.1146/annurev-chembioeng-061010-114209.Annu Rev Chem Biomol Eng. 2011.PMID:22432617Free PMC article.Review.
- Unlocking the potential of bacterial endophytes from medicinal plants for drug discovery.Zotchev SB.Zotchev SB.Microb Biotechnol. 2024 Feb;17(2):e14382. doi: 10.1111/1751-7915.14382. Epub 2024 Feb 12.Microb Biotechnol. 2024.PMID:38345183Free PMC article.Review.
- A comprehensive review of glycosylated bacterial natural products.Elshahawi SI, Shaaban KA, Kharel MK, Thorson JS.Elshahawi SI, et al.Chem Soc Rev. 2015 Nov 7;44(21):7591-697. doi: 10.1039/c4cs00426d.Chem Soc Rev. 2015.PMID:25735878Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical